MTHFR and non-small cell lung carcinoma: One retrospective analysis presented five polymorphisms in TS, MTHFR, and ERCC1 genes as molecular predictive markers for non-squamous NSCLC patients treated with pemetrexed, and platinum front-line chemotherapy showed the integrated analysis of the TS gene’s VNTR polymorphism and the MTHFR 677C>T indicated that patients who concurrently possessed the 3R allele in the TS gene and two C alleles in the MTHFR gene experienced a reduction in PFS (70).